Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial

ConclusionTreatment with bosentan in the early low-to-mild stages of PAD may prevent cardiovascular events and the need for lower limb revascularization in the Hispanic population.Trial Registration ClinicalTrials.gov identifier NCT25102012.

http://link.springer.com/10.1007/s40256-018-0307-y

Source: American Journal of Cardiovascular Drugs - November 12, 2018 Category: Cardiology Source Type: research